AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16803605
Drug: 4-day ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-day ranitidine bismuth citrate-based triple therapy (ranitidine bismuth citrate + amoxicillin + clarithromycin)
Trial: 12784408
Drug: Standard non-physiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard non-physiotherapy treatment (control group).
Trial: 30057908
Drug: Intradermal microdroplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal microdroplet injection
Trial: 30057908
Drug: Intradermal microdroplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal microdroplet group
Trial: 30057908
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Intramuscular injection)
Trial: 11941946
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg bd and Amoxicillin 1 g bd (LA)
Trial: 11941946
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg bd and Amoxicillin 1 g bd (OA)
Trial: 11941946
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg bd, Amoxicillin 1 g bd and Clarithromycin 500 mg bd (LAC)
Trial: 9921806
Drug: Daclizumab (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclizumab (1.0 mg/kg every other week for five doses)
Trial: 7573900
Drug: Intravenous propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous propofol anaesthesia (IVA)
Trial: 2304255
Drug: GOE anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GOE anesthesia and 0.2 mg epidural Bn every three hours (group B)
Trial: 2304255
Drug: GOE anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GOE anesthesia and 0.2 mg epidural Bn every six hours (group C)
Trial: 6994765
Drug: Guanfacine 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guanfacine 1.0 mg intravenously
Trial: 6670282
Drug: Chloroquine diphosphate
RxNorm normalized name: CHLOROQUINE DIPHOSPHATE, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine diphosphate (25 mg and 50 mg)
Trial: 6670282
Drug: Chloroquine diphosphate
RxNorm normalized name: CHLOROQUINE DIPHOSPHATE, (R)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine diphosphate (above 100 mg)
Trial: 30620668
Drug: pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pembrolizumab 200 mg every 3 weeks for up to 2 years
Trial: 30620668
Drug: platinum-based chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: platinum-based chemotherapy (four to six cycles)
Trial: 30620668
Drug: pembrolizumab (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pembrolizumab (after crossover from chemotherapy)
Trial: 27289488
Drug: Fixed low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed low dose of low-molecular-weight heparin (LMWH)
Trial: 27289488
Drug: Intermediate dose
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate dose of low-molecular-weight heparin (LMWH)
Trial: 24131674
Drug: EU paricalcitol
RxNorm normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EU paricalcitol dosing regimen (initial μg dose based on iPTH/80)
Trial: 24131674
Drug: US paricalcitol
RxNorm normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: US paricalcitol dosing regimen (initial dose of 0.04 μg/kg)
Trial: 22492669
Drug: Short message
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short message service maintenance treatment (SMSMT) for 9 months
Trial: 22492669
Drug: Short message
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short message service maintenance treatment (SMSMT)
Trial: 18478278
Drug: Ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 8 mg intramuscularly (arm A)
Trial: 18478278
Drug: Ondansetron 16
RxNorm normalized name: ondansetron 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 16 mg orally (arm B)
Trial: 15955118
Drug: Nicotine 0
RxNorm normalized name: nicotine 0.35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine 0 mg + Caffeine 0 mg
Trial: 15955118
Drug: Nicotine 1
RxNorm normalized name: nicotine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine 1 mg + Caffeine 50 mg
Trial: 15955118
Drug: Nicotine 1
RxNorm normalized name: nicotine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine 1 mg + Caffeine 100 mg
Trial: 15955118
Drug: Nicotine 2
RxNorm normalized name: nicotine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine 2 mg + Caffeine 50 mg
Trial: 15955118
Drug: Nicotine 2
RxNorm normalized name: nicotine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine 2 mg + Caffeine 100 mg
Trial: 12061413
Drug: Classroom cognitive‐behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Classroom cognitive‐behavioral treatment (CBT)
Trial: 12061413
Drug: Home‐based audio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home‐based audio relaxation treatment (HART)
Trial: 12061413
Drug: Delayed‐treatment control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed‐treatment control
Trial: 7668036
Drug: Adsorbed DT
RxNorm normalized name: L-DT
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adsorbed DT vaccine (n = 51)
Trial: 7668036
Drug: Fluid DT
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluid DT vaccine (n = 53)
Trial: 2206782
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg dipyridamole
Trial: 2206782
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg acetylsalicylic acid
Trial: 7192617
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group (subjected to 'conflict' 2 h daily for 12 weeks)
Trial: 28166324
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment with a systolic BP target of less than 120 mm Hg (n = 1317)
Trial: 28166324
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with a BP target of less than 140 mm Hg (n = 1319)
Trial: 23612453
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg per day until progression or unacceptable toxicity
Trial: 21942502
Drug: Post-therapy communication
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-therapy communication changes
Trial: 21942502
Drug: Post-therapy levels
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-therapy levels of problem solving and changes in wives' positivity
Trial: 14578410
Drug: Lomerizine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lomerizine 0.1 mg/kg
Trial: 14578410
Drug: Lomerizine 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lomerizine 0.3 mg/kg
Trial: 14578410
Drug: Lomerizine 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lomerizine 5 mg
Trial: 8279682
Drug: Weak ultrasonication
RxNorm normalized name: weakleaf bur ragweed pollen extract
DrugBank: Ambrosia confertiflora pollen (DB10872)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weak ultrasonication of ethanol solutions (40 kHz, 12 mW, 1 week)
Trial: 8279682
Drug: Treated aqueous
RxNorm normalized name: ethylcellulose aqueous dispersion type A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treated aqueous ethanol solution
Trial: 8279682
Drug: Treated solutions
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treated solutions
Trial: 2881574
Drug: Org 2305
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org 2305 15 mg (O 15)
Trial: 2881574
Drug: Org 2305
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org 2305 30 mg (O 30)
Trial: 2881574
Drug: Org 2305
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org 2305 60 mg (O 60)
Trial: 2881574
Drug: Diazepam 15
RxNorm normalized name: diazepam 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam 15 mg (DZ)
Trial: 18463885
Drug: Treatment started
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment started within the first hour after AAT (Group A, 20 patients)
Trial: 18463885
Drug: Treatment started
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment started more than 1 hour later and less than 16 hours after AAT (Group B, 17 patients)
Trial: 18463885
Drug: Treatment started
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment started after 24 hours or more (Group C, 15 patients)
Trial: 16612257
Drug: Enalapril administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril administration for 3 days
Trial: 30066385
Drug: Nicotine pre-loading
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine pre-loading (4 weeks of 21 mg nicotine patch use prior to quitting)
Trial: 30066385
Drug: Standard smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard smoking cessation medications with behavioral support
Trial: 27213492
Drug: Mindfulness‐Based Addiction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness‐Based Addiction Treatment (MBAT)
Trial: 25265494
Drug: vemurafenib and
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vemurafenib and cobimetinib (combination group)
Trial: 10517693
Drug: 0.05% betamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% betamethasone 17-21 dipropionate lotion (Diprosone lotion)
Trial: 7747540
Drug: Oral cyclosporin
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclosporin 5 mg/kg/day
Trial: 7747540
Drug: Topical dithranol
RxNorm normalized name: Zithranol
DrugBank: Anthralin (DB11157)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical dithranol and ultraviolet B therapy
Trial: 3083829
Drug: Ranitidine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (2 X 150 mg/d)
Trial: 3083829
Drug: Omeprazole (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (5 mg and 10 mg/d)
Trial: 3083829
Drug: Ranitidine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (2 X 25 mg/d)
Trial: 25135997
Drug: Rituximab treatment
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab treatment with vitamin D levels ≤ 8 ng/mL
Trial: 25135997
Drug: Rituximab treatment
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab treatment with vitamin D levels > 8 ng/mL
Trial: 25135997
Drug: Rituximab treatment
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab treatment without vitamin D deficiency (levels ≤ 8 ng/mL or > 8 ng/mL)
Trial: 27206943
Drug: Ezetimibe (EZE)
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe (EZE) 10 mg
Trial: 15924587
Drug: Ezetimibe (EZE)
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe (EZE) co-administered with atorvastatin (ATV)
Trial: 31168711
Drug: Eight sessions
RxNorm normalized name: Alternanthera sessilis extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eight sessions of moderate intensity aerobic exercise along with eight self-management modules during chemotherapy.
Trial: 29683702
Drug: Prolonged exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged exposure therapy (PE) alone
Trial: 29683702
Drug: Prolonged exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged exposure therapy (PE) + alcohol use disorder treatment
Trial: 29683702
Drug: Prolonged exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged exposure therapy (PE) + nicotine use disorder treatment
Trial: 16263773
Drug: 480 micromol
RxNorm normalized name: BENZALKONIUM CHLORIDE 0.3068 g in 236 mL TOPICAL SOAP [MicroGold Anti-Bacterial Waterless Hand (4 oz.)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 480 micromol x kg(‐1) x h(‐1) intravenous amino acid solution for 5 h
Trial: 16263773
Drug: 960 micromol
RxNorm normalized name: BENZALKONIUM CHLORIDE 0.3068 g in 236 mL TOPICAL SOAP [MicroGold Anti-Bacterial Waterless Hand (4 oz.)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 960 micromol x kg(‐1) x h(‐1) intravenous amino acid solution for 5 h
Trial: 16263773
Drug: 960 micromol
RxNorm normalized name: BENZALKONIUM CHLORIDE 0.3068 g in 236 mL TOPICAL SOAP [MicroGold Anti-Bacterial Waterless Hand (4 oz.)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 960 micromol x kg(‐1) x h(‐1) intravenous amino acid solution for 24 h
Trial: 8299406
Drug: EDTA treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDTA treatment (20 repeated infusions of 3 grams over 5-9 weeks)
Trial: 27267753
Drug: MEDI-551 (0.1-10.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI-551 (0.1-10.0 mg/kg)
Trial: 19024525
Drug: Domestic docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Domestic docetaxel (70 mg/m2 on D2) combined with doxorubicin (40 mg/m2 on D1)
Trial: 19024525
Drug: Taxotere (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxotere (70 mg/m2 on D2) combined with doxorubicin (40 mg/m2 on D1)
Trial: 10547170
Drug: Pharmacist-initiated interventions
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmacist-initiated interventions involving anti-infective agents
Trial: 8975568
Drug: Combined use
RxNorm normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined use of opiate premedication, regional blocking, and parenteral diclophenak-Na before and after the operation
Trial: 31689890
Drug: Iodine supplementation
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine supplementation (225 ug/day, potassium iodide tablets)
Trial: 25146513
Drug: Fluvastatin IR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin IR 40 mg twice daily
Trial: 12693793
Drug: Once-daily budesonide/formoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily budesonide/formoterol (160/4.5 microg, two inhalations)
Trial: 12693793
Drug: Twice-daily budesonide/formoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-daily budesonide/formoterol (160/4.5 microg, one inhalation)
Trial: 12693793
Drug: Budesonide (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide (400 microg) once-daily
Trial: 10711617
Drug: 0.12% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine solution rinsed twice during 4 hours
Trial: 10711617
Drug: 0.12% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine solution rinsed three times during 24 hours
Trial: 3903382
Drug: Flatoril (dimethicone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flatoril (dimethicone 200 mg and clebopride 0.5 mg)
Trial: 27918968
Drug: Web-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based cognitive behavioral therapy with asynchronous therapeutic support
Trial: 23492647
Drug: ARB+C (amlodipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARB+C (amlodipine 5mg + typical dosage of ARBs)
Trial: 22227229
Drug: mpHBV (modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mpHBV (modified process hepatitis B vaccine)
Trial: 18690015
Drug: RECOMBIVAX HB
RxNorm normalized name: Recombivax HB
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RECOMBIVAX HB (control vaccine)
Trial: 18690015
Drug: mpHBV and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mpHBV and RECOMBIVAX HB (control vaccine)
Trial: 16957573
Drug: Candesartan 16
RxNorm normalized name: candesartan 16 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 16 mg/day for 3 months
Trial: 16957573
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment change)
Trial: 11097593
Drug: Topical proparacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical proparacaine hydrochloride 0.5%
Trial: 11097593
Drug: Exposure to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure to oleoresin capsicum (pepper spray)
Trial: 9024449
Drug: CRP-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP-guided treatment (group 1)
Trial: 9024449
Drug: CRP-guided treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP-guided treatment (group 2a)
Trial: 9024449
Drug: At least
RxNorm normalized name: Lovaza 1000 MG (at least 900 MG) Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At least 5-day treatment (group 2b)
Trial: 1332213
Drug: Fragmin administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fragmin administered subcutaneously once daily (200 U(anti‐FXa)/kg/24h)
Trial: 1332213
Drug: Fragmin administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fragmin administered subcutaneously twice daily (100 U(anti‐FXa)/kg/12h)
Trial: 22169794
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg daily and Sorafenib 400 mg twice daily (MTD)
Trial: 18684771
Drug: Sublingual nitroglycerin
RxNorm normalized name: nitroglycerin Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual nitroglycerin (NTG) 500 microg
Trial: 18684771
Drug: Sublingual nitroglycerin
RxNorm normalized name: nitroglycerin Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual nitroglycerin (NTG) 375 microg
Trial: 18684771
Drug: Sublingual nitroglycerin
RxNorm normalized name: nitroglycerin Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual nitroglycerin (NTG) 250 microg
Trial: 17313008
Drug: Shu‐Mu point
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shu‐Mu point combination
Trial: 17313008
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (Danazol)
Trial: 10721508
Drug: Manual physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual physical therapy combined with supervised exercise
Trial: 8936356
Drug: ORG 2766
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORG 2766 0.1 mg
Trial: 8936356
Drug: ORG 2766
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORG 2766 0.4 mg
Trial: 8936356
Drug: ORG 2766
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORG 2766 2 mg
Trial: 6388715
Drug: Ornithine-8-vasopressin injection
RxNorm normalized name: Vasopressin Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ornithine-8-vasopressin injection
Trial: 20488250
Drug: Usual exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual exercise therapy (UC; usual care)
Trial: 12776579
Drug: DHEP formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEP formulation with lecithin
Trial: 12776579
Drug: Marketed DHEP
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marketed DHEP formulation without lecithin
Trial: 1673937
Drug: Intravenous metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous metronidazole 1.0 g
Trial: 7323709
Drug: 5 MIU
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 MIU of penicillin intravenously twice daily for 4 days, plus intraincisional injection of penicillin at wound closure
Trial: 7323709
Drug: 2 MIU
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 MIU penicillin and 0.5 g streptomycin twice daily for 5 days (control group)